Issues in antithrombin therapy for UA/NSTEMI

Joseph S Alpert, A. J. Budaj, E. P. Gurfinkel, T. D. Henry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.

Original languageEnglish (US)
JournalEuropean Heart Journal, Supplement
Volume3
Issue numberJ
DOIs
StatePublished - 2001

Fingerprint

Antithrombins
Low Molecular Weight Heparin
Platelet Membrane Glycoprotein IIb
Advisory Committees
Guidelines
Unstable Angina
Therapeutics
Cardiology
Heparin
Non-ST Elevated Myocardial Infarction

Keywords

  • Antithrombin
  • Guidelines
  • Heparin
  • Low-molecular-weight heparin
  • Unstable angina

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Issues in antithrombin therapy for UA/NSTEMI. / Alpert, Joseph S; Budaj, A. J.; Gurfinkel, E. P.; Henry, T. D.

In: European Heart Journal, Supplement, Vol. 3, No. J, 2001.

Research output: Contribution to journalArticle

Alpert, Joseph S ; Budaj, A. J. ; Gurfinkel, E. P. ; Henry, T. D. / Issues in antithrombin therapy for UA/NSTEMI. In: European Heart Journal, Supplement. 2001 ; Vol. 3, No. J.
@article{6de76f6c627d41cca80f3225ca705498,
title = "Issues in antithrombin therapy for UA/NSTEMI",
abstract = "In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.",
keywords = "Antithrombin, Guidelines, Heparin, Low-molecular-weight heparin, Unstable angina",
author = "Alpert, {Joseph S} and Budaj, {A. J.} and Gurfinkel, {E. P.} and Henry, {T. D.}",
year = "2001",
doi = "10.1016/S1520-765X(01)90136-1",
language = "English (US)",
volume = "3",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "J",

}

TY - JOUR

T1 - Issues in antithrombin therapy for UA/NSTEMI

AU - Alpert, Joseph S

AU - Budaj, A. J.

AU - Gurfinkel, E. P.

AU - Henry, T. D.

PY - 2001

Y1 - 2001

N2 - In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.

AB - In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIa antagonists would be helpful, as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization.

KW - Antithrombin

KW - Guidelines

KW - Heparin

KW - Low-molecular-weight heparin

KW - Unstable angina

UR - http://www.scopus.com/inward/record.url?scp=0034880174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034880174&partnerID=8YFLogxK

U2 - 10.1016/S1520-765X(01)90136-1

DO - 10.1016/S1520-765X(01)90136-1

M3 - Article

AN - SCOPUS:0034880174

VL - 3

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - J

ER -